Literature DB >> 19350293

Evaluating the resistance to posaconazole by E-test and CLSI broth microdilution methodologies of Candida spp. and pathogenic moulds.

R Araujo1, S Costa-de-Oliveira, I Coutinho, A G Rodrigues, C Pina-Vaz.   

Abstract

E-test methodology was compared with Clinical and Laboratory Standards Institute (CLSI) broth microdilution, particularly concerning the detection of resistance to posaconazole among clinical fungal isolates. The susceptibility of a large set of fungal strains (n = 300) was evaluated following 24 and 48 h in two different culture media (RPMI 1640 and Sabouraud agar). Fungal strains were highly susceptible to posaconazole; however, few less susceptible strains were found, mostly regarding Candida albicans, Candida glabrata, Acremonium sp., Cladosporium sp. and Scedosporium apiospermum. Broth microdilution and E-test methods provided similar results for posaconazole-susceptible strains, while the less susceptible fungal strains (10.3% of the strains showed MIC > or =2 microg/mL) resulted in higher discrepancies between the two methodologies, particularly concerning Candida spp. E-test susceptibility values were critically affected by the pH of the culture media. Sabouraud medium provided similar susceptibility results for moulds to those for RPMI, soon after 24 h. Posaconazole resistance was rare in this study, but routine susceptibility methods, such as the E-test, should be able to detect fungal strains with reduced susceptibility. E-test methodology still needs improvements to recognise accurately strains less susceptible to posaconazole.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19350293     DOI: 10.1007/s10096-009-0736-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species.

Authors:  M A Pfaller; S A Messer; K Mills; A Bolmström; R N Jones
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

2.  Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates.

Authors:  D T A Te Dorsthorst; J W Mouton; C J P van den Beukel; H A L van der Lee; J F G M Meis; P E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

3.  Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2006-08-30       Impact factor: 5.948

4.  Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi.

Authors:  Shawn A Messer; Daniel J Diekema; Richard J Hollis; Linda B Boyken; Shailesh Tendolkar; Jennifer Kroeger; Michael A Pfaller
Journal:  J Clin Microbiol       Date:  2007-01-31       Impact factor: 5.948

5.  Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.

Authors:  A Espinel-Ingroff; B Arthington-Skaggs; N Iqbal; D Ellis; M A Pfaller; S Messer; M Rinaldi; A Fothergill; D L Gibbs; A Wang
Journal:  J Clin Microbiol       Date:  2007-04-11       Impact factor: 5.948

6.  Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.

Authors:  Jesús Guinea; Teresa Peláez; Luis Alcalá; Emilio Bouza
Journal:  Diagn Microbiol Infect Dis       Date:  2006-12-01       Impact factor: 2.803

7.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

8.  A first Portuguese epidemiological survey of fungaemia in a university hospital.

Authors:  S Costa-de-Oliveira; C Pina-Vaz; D Mendonça; A Gonçalves Rodrigues
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-19       Impact factor: 3.267

9.  Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2007-12-19       Impact factor: 5.948

10.  Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei.

Authors:  Vishnu Chaturvedi; Rama Ramani; Mahmoud A Ghannoum; Scott B Killian; Nicole Holliday; Cindy Knapp; Luis Ostrosky-Zeichner; Shawn A Messer; Michael A Pfaller; Naureen J Iqbal; Beth A Arthington-Skaggs; Jose A Vazquez; Tin Sein; John H Rex; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

View more
  3 in total

1.  Neonatal intensive care unit candidemia: epidemiology, risk factors, outcome, and critical review of published case series.

Authors:  A Spiliopoulou; G Dimitriou; E Jelastopulu; I Giannakopoulos; E D Anastassiou; Myrto Christofidou
Journal:  Mycopathologia       Date:  2011-11-11       Impact factor: 2.574

Review 2.  Unpredictable susceptibility of emerging clinical moulds to tri-azoles: review of the literature and upcoming challenges for mould identification.

Authors:  R Araujo; M Oliveira; A Amorim; B Sampaio-Maia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-18       Impact factor: 3.267

3.  A novel flucytosine-resistant yeast species, Candida pseudoaaseri, causes disease in a cancer patient.

Authors:  Roland Pfüller; Yvonne Gräser; Marcel Erhard; Marizeth Groenewald
Journal:  J Clin Microbiol       Date:  2011-10-05       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.